405 related articles for article (PubMed ID: 27394638)
1. Inhibitory activity of avibactam against selected β-lactamases expressed in an isogenic Escherichia coli strain.
Giani T; Cannatelli A; Di Pilato V; Testa R; Nichols WW; Rossolini GM
Diagn Microbiol Infect Dis; 2016 Sep; 86(1):83-5. PubMed ID: 27394638
[TBL] [Abstract][Full Text] [Related]
2. Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single β-lactamases.
Papp-Wallace KM; Bajaksouzian S; Abdelhamed AM; Foster AN; Winkler ML; Gatta JA; Nichols WW; Testa R; Bonomo RA; Jacobs MR
Diagn Microbiol Infect Dis; 2015 May; 82(1):65-9. PubMed ID: 25737290
[TBL] [Abstract][Full Text] [Related]
3. Inhibition by Avibactam and Clavulanate of the β-Lactamases KPC-2 and CTX-M-15 Harboring the Substitution N
Ourghanlian C; Soroka D; Arthur M
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069651
[TBL] [Abstract][Full Text] [Related]
4. The postantibiotic effect and post-β-lactamase-inhibitor effect of ceftazidime, ceftaroline and aztreonam in combination with avibactam against target Gram-negative bacteria.
Pillar CM; Stoneburner A; Shinabarger DL; Krause KM; Nichols WW
Lett Appl Microbiol; 2016 Aug; 63(2):96-102. PubMed ID: 27221329
[TBL] [Abstract][Full Text] [Related]
5. Activity of ceftazidime/avibactam against isogenic strains of Escherichia coli containing KPC and SHV β-lactamases with single amino acid substitutions in the Ω-loop.
Winkler ML; Papp-Wallace KM; Bonomo RA
J Antimicrob Chemother; 2015 Aug; 70(8):2279-86. PubMed ID: 25957381
[TBL] [Abstract][Full Text] [Related]
6. The pharmacodynamics of avibactam in combination with ceftaroline or ceftazidime against β-lactamase-producing Enterobacteriaceae studied in an in vitro model of infection.
MacGowan A; Tomaselli S; Noel A; Bowker K
J Antimicrob Chemother; 2017 Mar; 72(3):762-769. PubMed ID: 28039276
[TBL] [Abstract][Full Text] [Related]
7. Activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double β-lactamases under high and low permeability conditions.
Blanco-Martín T; Alonso-García I; González-Pinto L; Outeda-García M; Guijarro-Sánchez P; López-Hernández I; Pérez-Vázquez M; Aracil B; López-Cerero L; Fraile-Ribot P; Oliver A; Vázquez-Ucha JC; Beceiro A; Bou G; Arca-Suárez J;
Int J Antimicrob Agents; 2024 May; 63(5):107150. PubMed ID: 38513748
[TBL] [Abstract][Full Text] [Related]
8. Variants of β-lactamase KPC-2 that are resistant to inhibition by avibactam.
Papp-Wallace KM; Winkler ML; Taracila MA; Bonomo RA
Antimicrob Agents Chemother; 2015 Jul; 59(7):3710-7. PubMed ID: 25666153
[TBL] [Abstract][Full Text] [Related]
9. In vitro susceptibility of characterized β-lactamase-producing Gram-negative bacteria isolated in Japan to ceftazidime-, ceftaroline-, and aztreonam-avibactam combinations.
Yoshizumi A; Ishii Y; Aoki K; Testa R; Nichols WW; Tateda K
J Infect Chemother; 2015 Feb; 21(2):148-51. PubMed ID: 25444674
[TBL] [Abstract][Full Text] [Related]
10. Structural and sequence analysis of class A β-lactamases with respect to avibactam inhibition: impact of Ω-loop variations.
Lahiri SD; Bradford PA; Nichols WW; Alm RA
J Antimicrob Chemother; 2016 Oct; 71(10):2848-55. PubMed ID: 27402011
[TBL] [Abstract][Full Text] [Related]
11. Avibactam and inhibitor-resistant SHV β-lactamases.
Winkler ML; Papp-Wallace KM; Taracila MA; Bonomo RA
Antimicrob Agents Chemother; 2015 Jul; 59(7):3700-9. PubMed ID: 25691639
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of a Ceftazidime-Avibactam combination in a murine model of Septicemia caused by Enterobacteriaceae species producing ampc or extended-spectrum β-lactamases.
Levasseur P; Girard AM; Lavallade L; Miossec C; Pace J; Coleman K
Antimicrob Agents Chemother; 2014 Nov; 58(11):6490-5. PubMed ID: 25136016
[TBL] [Abstract][Full Text] [Related]
13. Molecular Basis of Class A β-Lactamase Inhibition by Relebactam.
Tooke CL; Hinchliffe P; Lang PA; Mulholland AJ; Brem J; Schofield CJ; Spencer J
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31383664
[TBL] [Abstract][Full Text] [Related]
14. Impact of defined cell envelope mutations in Escherichia coli on the in vitro antibacterial activity of avibactam/β-lactam combinations.
McLeod SM; Patey SA; Huband MD; Nichols WW
Int J Antimicrob Agents; 2017 Apr; 49(4):437-442. PubMed ID: 28242258
[TBL] [Abstract][Full Text] [Related]
15. Unusual Escherichia coli PBP 3 Insertion Sequence Identified from a Collection of Carbapenem-Resistant Enterobacteriaceae Tested
Zhang Y; Kashikar A; Brown CA; Denys G; Bush K
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559260
[TBL] [Abstract][Full Text] [Related]
16. Molecular Characterization of Carbapenem-Nonsusceptible Enterobacterial Isolates Collected during a Prospective Interregional Survey in France and Susceptibility to the Novel Ceftazidime-Avibactam and Aztreonam-Avibactam Combinations.
Dupont H; Gaillot O; Goetgheluck AS; Plassart C; Emond JP; Lecuru M; Gaillard N; Derdouri S; Lemaire B; Girard de Courtilles M; Cattoir V; Mammeri H
Antimicrob Agents Chemother; 2016 Jan; 60(1):215-21. PubMed ID: 26482307
[TBL] [Abstract][Full Text] [Related]
17. First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate.
Humphries RM; Yang S; Hemarajata P; Ward KW; Hindler JA; Miller SA; Gregson A
Antimicrob Agents Chemother; 2015 Oct; 59(10):6605-7. PubMed ID: 26195508
[TBL] [Abstract][Full Text] [Related]
18. In vitro antibacterial activity of the ceftazidime-avibactam combination against enterobacteriaceae, including strains with well-characterized β-lactamases.
Levasseur P; Girard AM; Miossec C; Pace J; Coleman K
Antimicrob Agents Chemother; 2015 Apr; 59(4):1931-4. PubMed ID: 25583732
[TBL] [Abstract][Full Text] [Related]
19. Impaired Inhibition by Avibactam and Resistance to the Ceftazidime-Avibactam Combination Due to the D
Compain F; Arthur M
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28461318
[TBL] [Abstract][Full Text] [Related]
20. Reclaiming the efficacy of β-lactam-β-lactamase inhibitor combinations: avibactam restores the susceptibility of CMY-2-producing Escherichia coli to ceftazidime.
Papp-Wallace KM; Winkler ML; Gatta JA; Taracila MA; Chilakala S; Xu Y; Johnson JK; Bonomo RA
Antimicrob Agents Chemother; 2014 Aug; 58(8):4290-7. PubMed ID: 24820081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]